TheraVectys Immunize Revenue and Competitors

Paris Cedex 15,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • TheraVectys Immunize's estimated annual revenue is currently $3.4M per year.(i)
  • TheraVectys Immunize's estimated revenue per employee is $155,000

Employee Data

  • TheraVectys Immunize has 22 Employees.(i)
  • TheraVectys Immunize grew their employee count by 5% last year.

TheraVectys Immunize's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$99.4M45840%N/AN/A
#2
$20.6M13322%N/AN/A
#3
$156.1M146-70%$145MN/A
#4
$3.5M45-25%$150MN/A
#5
$1.6M210%$459.5MN/A
#6
$67.3M31016%$180.7MN/A
#7
$8.5M55-2%N/AN/A
#8
$256.3M10259%$168.5MN/A
#9
$2.8M18-33%N/AN/A
#10
$9.1M59-9%N/AN/A
Add Company

What Is TheraVectys Immunize?

THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology. Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology' and IP's versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market. With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health.

keywords:N/A

N/A

Total Funding

22

Number of Employees

$3.4M

Revenue (est)

5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$36.5M158-3%N/A
#2
$51.1M36513%N/A
#3
$35M5774%N/A